Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients
International Journal of Molecular Sciences · 09.09.2023 · 24 (18) · 13892
DOI: 10.3390/ijms241813892 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.09.2023. Verfasst von Javier Modrego und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Riesgo Cardiovascular y Microbiota, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madri…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Heart Failure. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Regional Development’s funds, SEC-ROVI Research Grant for the Promotion of Research in Heart Failure 2017 of the Spanish Society of Cardiology.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
There is a lack of direct evidence regarding gut microbiota dysbiosis and changes in short-chain fatty acids (SCFAs) in heart failure (HF) patients. We sought to assess any association between gut microbiota composition, SCFA production, clinical parameters, and the inflammatory profile in a cohort of newly diagnosed HF patients. In this longitudinal prospective study, we enrolled eighteen newly diagnosed HF patients. At admission and after 12 months, blood samples were collected for the assessment of proinflammatory cytokines, monocyte populations, and endothelial dysfunction, and stool samples were collected for analysis of gut microbiota composition and quantification of SCFAs. Twelve months after the initial HF episode, patients demonstrated improved clinical parameters and reduced inflammatory state and endothelial dysfunction. This favorable evolution was associated with a reversal of microbiota dysbiosis, consisting of the increment of health-related bacteria, such as genus Bifidobacterium, and levels of SCFAs, mainly butyrate. Furthermore, there was a decrease in the abundance of pathogenic bacteria. In vitro, fecal samples collected after 12 months of follow-up exhibited lower inflammation than samples collected at admission. In conclusion, the favorable progression of HF patients after the initial episode was linked to the reversal of gut microbiota dysbiosis and increased SCFA production, particularly butyrate. Whether restoring butyrate levels or promoting the growth of butyrate-producing bacteria could serve as a complementary treatment for these patients deserves further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Riesgo Cardiovascular y Microbiota, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Servicio de Cardiología, Hospital Clínico de San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
- Instituto de Agroquímica y Tecnología de los Alimentos (IATA-CSIC), 46980 Paterna, Spain.
- Servicio de Cardiología, Hospital Universitario Severo Ochoa, 28914 Leganés, Spain.
- Departamento de Medicina, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.
ORCID-Profile: Javier Modrego, Christine Bäuerl, Silvia Sánchez-González, Alberto Esteban-Fernández, María Carmen Collado, Dulcenombre Gómez-Garre
Förderung
- Instituto de Salud Carlos III
- European Regional Development’s funds
- SEC-ROVI Research Grant for the Promotion of Research in Heart Failure 2017 of the Spanish Society of Cardiology
- Biomedical Research Networking Centre in Cardiovascular Diseases
Zitieren
APA
Modrego, J., Ortega-Hernández, A., Goirigolzarri, J., Restrepo-Córdoba, M. A., Bäuerl, C., Cortés-Macías, E., Sánchez-González, S., Esteban-Fernández, A., Pérez-Villacastín, J., Collado, M. C., & Gómez-Garre, D. (2023). Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients. International Journal of Molecular Sciences, 24(18), 13892. https://doi.org/10.3390/ijms241813892
Vancouver
Modrego J, Ortega-Hernández A, Goirigolzarri J, Restrepo-Córdoba MA, Bäuerl C, Cortés-Macías E, et al. Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients. International Journal of Molecular Sciences. 2023;24(18):13892. doi:10.3390/ijms241813892
BibTeX
@article{Modrego2023,
author = {Modrego, Javier and Ortega-Hernández, Adriana and Goirigolzarri, Josebe and Restrepo-Córdoba, María Alejandra and Bäuerl, Christine and Cortés-Macías, Erika and Sánchez-González, Silvia and Esteban-Fernández, Alberto and Pérez-Villacastín, Julián and Collado, María Carmen and Gómez-Garre, Dulcenombre},
title = {Gut Microbiota and Derived Short-Chain Fatty Acids Are Linked to Evolution of Heart Failure Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {18},
pages = {13892},
doi = {10.3390/ijms241813892}
}
EUVIMED